BamSEC and AlphaSense Join Forces
Learn More

iTeos Therapeutics Inc.

NASDAQ: ITOS    
Share price (8/22/25): $10.19    
Market cap (8/22/25): $450 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 29 pages Form of Contingent Value Rights Agreement
12/34/56
EX-10.3
from 8-K 6 pages First Amendment to the Employment Agreement Between iTeos Therapeutics, Inc. and David Feltquate
12/34/56
EX-10.2
from 8-K 6 pages First Amendment to the Employment Agreement Between iTeos Therapeutics, Inc. and Matt Call
12/34/56
EX-10.1
from 8-K 6 pages First Amendment to the Employment Agreement Between iTeos Therapeutics, Inc. and Michel Detheux
12/34/56
EX-10.15
from 10-K 15 pages Employment Agreement This Employment Agreement (“Agreement”) Is Made Between iTeos Therapeutics, Inc. (The “Company”), and David Feltquate (The “Executive”) and Is Effective as of July 31, 2024 (The “Effective Date”). Whereas, the Company Desires to Employ the Executive and the Executive Desires to Be Employed by the Company on the Terms and Conditions Contained Herein. Now, Therefore, in Consideration of the Mutual Covenants and Agreements Herein Contained and Other Good and Valuable Consideration, the Receipt and Sufficiency of Which Is Hereby Acknowledged, the Parties Agree as Follows: 1. Employment
12/34/56
EX-10.2
from 10-Q 12 pages Consultancy Letter Agreement
12/34/56
EX-10.1
from 10-Q 10 pages Consultancy Letter Agreement
12/34/56
EX-10
from 10-K 10 pages Consultancy Letter Agreement
12/34/56
EX-10
from 10-K 7 pages Informal Translation From the Original French
12/34/56
EX-10
from 10-K 4 pages After Having Explained the Following: It Has Been Agreed as Follows
12/34/56
EX-10
from 10-K 3 pages Amendment No. 2 to Collaboration and License Agreement
12/34/56
EX-10
from 10-K 3 pages Amendment No. 1 to Collaboration and License Agreement
12/34/56
EX-10.1
from 10-Q 2 pages First Amendment to the ITeos Therapeutics, Inc. 2020 Employee Stock Purchase Plan
12/34/56
EX-10.15
from 10-K 11 pages Translated From the Original French Employment Contract
12/34/56
EX-10.14
from 10-K 41 pages Lease Agreement
12/34/56
EX-10.1
from 10-Q 128 pages Certain Information (Indicated by “[***]”) and Schedules Have Been Excluded From This Agreement Because Such Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Collaboration and License Agreement Between Glaxosmithkline Intellectual Property (No. 4) Limited and ITeos Belgium S.A
12/34/56
EX-10.1
from 10-Q 38 pages Background
12/34/56
EX-10.13
from S-1/A 7 pages Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement
12/34/56
EX-10.12
from S-1/A 15 pages Employment Agreement
12/34/56
EX-10.11
from S-1/A 15 pages Employment Agreement
12/34/56